HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.
WOC 2022

Jerome Chelliah

Jerome Chelliah, Speaker at Obesity Events
HerMD Cincinnati, United States
Title : Weight Changes in Women Treated with Flibanserin for Hypoactive Sexual Desire Disorder at a Women’s Health Specialty Clinic


Flibanserin is a multifunctional serotonergic (5-HT) medication that acts as a 5-HT1A receptor agonist and
5-HT2A receptor antagonist. Findings from in vitro studies suggest it decreases serotonin and increases
dopamine and norepinephrine activity in select regions of the cerebral cortex. Although only approved in the
U.S. to treat premenopausal women with hypoactive sexual desire disorder (HSDD), a condition estimated
to affect 1 in 10 women in the U.S., clinical studies in postmenopausal women have shown similar safety
and efficacy.
Patients with HSDD at our women’s health specialty clinic treated with flibanserin have reported weight loss.
In addition, there are reports of weight loss secondary to flibanserin in the literature. Therefore, to further
explore weight changes during flibanserin treatment at our clinic, we included weight as an objective in a
retrospective electronic health record (EHR) review study of women with HSDD/low libido treated with
flibanserin between September 1, 2015, to August 31, 2020.
Weight is captured at our clinical as a vital sign during routine follow-up visits and served as the data source
for weight measurements in the study. We evaluated valid weight changes for women with documented
flibanserin usage. Flibanserin usage was confirmed by reviewing patient free text encounter notes and
clinician assessment notes. For a weight change to be considered valid in the study, the change must have
occurred during documented flibanserin usage and have a baseline measurement (i.e., before starting
flibanserin) and treatment duration or stop date. In addition, we reviewed patient medication lists to determine
if any concomitant medications may have contributed to weight changes. It is important to note that
medications prescribed outside our EHR are not captured in the patient's medication list.

What will audience learn from your presentation?

1. Describe the role of flibanserin in the treatment of HSDD in women with obesity concerned about weight gain secondary to flibanserin treatment

2. Summarize average weight changes observed during flibanserin treatment among women with HSDD treated at a women’s health specialty clinic

3. Discuss the prevalence of HSDD and weight gain among women as they transition through menopause as observed at a women’s health specialty clinic

4. Discuss the value and limitations of retrospective EHR review studies to capture real-world patient data


Dr.Jerome Chelliah is a board-certified OBGYN with a focus on menopause, sexual health, and lifestyle medicine. He is a graduate of the University of California, San Francisco School of Medicine (M.D.) and Johns Hopkins Bloomberg School of Public Health (MPH). He has held physician leadership roles at the Cleveland Clinic and Kaiser Permanente. He has published and presented at numerous national conferences including American College of Obstetrics and Gynecology (ACOG), Association of Professors of Gynecology and Obstetrics (APGO) and The American Geriatric Association. He serves on the board of several Femtech companies including Ava Women, Prenome, and Medicem.